TapImmune announces results from HER2/neu interim study on breast cancer

TapImmune Inc. has announced that an interim safety analysis on the first five breast cancer patients treated with HER2/neu Class II antigens at Mayo Clinic, Rochester, MN., did not show any serious adverse events.

Read more...

No comments:

Post a Comment

8 Ways to Trick Yourself Thin

8 Ways to Trick Yourself Thin An article from By Chris Freytag The formula for weight loss may be simple-take in fewer calories ...